SEHK:1866
SEHK:1866Chemicals

3 Undervalued Asian Small Caps With Insider Buying

Amidst global market fluctuations, Asian small-cap stocks have been navigating a challenging landscape influenced by AI-related valuation concerns and economic policy shifts. Despite these headwinds, certain small-cap companies in Asia are garnering attention due to insider buying activities, suggesting potential confidence in their underlying value and growth prospects.
SEHK:8168
SEHK:8168Capital Markets

Asian Market Insights: Promising Penny Stocks For November 2025

As global markets grapple with concerns over AI valuations and economic uncertainties, the Asian market presents a unique landscape for investors. Penny stocks, often overlooked but still significant, offer potential opportunities when supported by strong financials. In this article, we explore three penny stocks in Asia that stand out for their robust balance sheets and potential for long-term growth.
SEHK:981
SEHK:981Semiconductor

Why Semiconductor Manufacturing International (SEHK:981) Is Down 6.4% After Reporting Strong Q3 Earnings Growth

On November 13, 2025, Semiconductor Manufacturing International Corporation reported earnings for the nine months ended September 30, 2025, with sales rising to CNY 49.51 billion and net income improving to CNY 3.82 billion compared to the previous year. This marks a period of clear profitability growth for the company, with basic and diluted earnings per share from continuing operations each increasing to CNY 0.48, reflecting operational momentum. We'll explore how this strong revenue and...
SEHK:1801
SEHK:1801Biotechs

Is Mazdutide’s Phase 3 Success Reshaping the Investment Case for Innovent Biologics (SEHK:1801)?

Innovent Biologics announced that its Phase 3 GLORY-2 clinical trial of mazdutide, a dual GCG/GLP-1 receptor agonist, in Chinese adults with obesity met all primary and secondary endpoints, and the company intends to submit a new drug application in China for weight management use. This marks mazdutide as the first innovative endocrinology and metabolic drug in China with clinical results published in The New England Journal of Medicine, highlighting its international scientific...
SEHK:1816
SEHK:1816Renewable Energy

CGN Power (SEHK:1816) Valuation in Focus After Launch of Zhaoyuan Unit 1 Construction

CGN Power (SEHK:1816) has kicked off full-scale construction of its Zhaoyuan Unit 1 reactor, leveraging advanced HPR1000 technology. This latest milestone signals ongoing growth ambitions and an increasingly prominent role in the nuclear power sector. See our latest analysis for CGN Power. The fresh momentum from CGN Power’s Zhaoyuan Unit 1 project comes after a year in which its share price has climbed 10.26% and total shareholder return over five years is an impressive 129.10%. This kind of...
SEHK:1910
SEHK:1910Luxury

What Samsonite Group (SEHK:1910)'s Margin Gains Amid Softer Sales Reveal About Its Earnings Resilience

Samsonite Group S.A. reported its third quarter and nine-month 2025 earnings, with quarterly sales at US$872.7 million and net income reaching US$73.5 million, compared to US$877.7 million and US$66.2 million, respectively, in the prior year. While quarterly sales saw a slight decline year-on-year, the company managed to improve its quarterly net income, highlighting an increased profitability despite softer revenues. We'll now analyze how Samsonite’s improved quarterly profitability,...